All In Biotech

Drug Trial Radar · NCT03902184

IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

170

Actual

Start

May 22, 2019

Primary completion

Jan 8, 2026

Study completion Jan 8, 2026

Sponsor

Lead sponsor
Innate PharmaIndustry
Sponsor type
Industry
First posted
Apr 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.

Conditions

  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides/Sezary Syndrome

Interventions

  • IPH4102Biological

    Patients will receive a flat dose of 750mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From the first dose until study completion, an expected average of 2 years

Locations

53 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California, Los Angeles (UCLA) - Medical Center

    Los Angeles, California

  • Irvine Medical Center

    Orange, California

  • Stanford University

    Stanford, California

  • Moffitt Cancer Center

    Tampa, Florida

  • University of South Florida

    Tampa, Florida

  • Northwestern University The Feinberg School of Medicine

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Universal Dermatology, PLLC68

    Fairport, New York

  • Columbia University Department of Dermatology

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Inova Health Care Services

    Fairfax, Virginia

  • Universitätsklinik für Dermatologie Medizinische Universität Graz

    Graz, Austria

  • Medizinische Universitaet Wien

    Vienna, Austria

  • Institut Jules Bordet

    Brussels, Belgium

  • UZ Leuven - campus Gasthuisberg

    Leuven, Belgium

  • Centre Hospitalier Universitaire (CHU) de Liege

    Liège, Belgium

  • CHU de Bordeaux Saint André

    Bordeaux, France

  • CHRU de Tours, Hôpital Trousseau

    Chambray-lès-Tours, France

  • CHU Henri Mondor

    Créteil, France

  • CHRU de Lille - Hopital Claude Huriez

    Lille, France

  • Centre Hospitalier Lyon-Sud

    Lyon, France

  • Institut Paoli-Calmettes

    Marseille, France

  • CHRU de Montpellier - Hopital Saint Eloi

    Montpellier, France

  • Hôpital Saint-Louis

    Paris, France

  • Hôpital Charles Nicolle-CHU de Rouen Clinique Dermatologie

    Rouen, France

  • IUCT Oncopôle

    Toulouse, France

  • Charite - Universitaetsmedizin Berlin

    Berlin, Germany

  • Ruhr-University Bochum

    Bochum, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Universitaetsklinikum Halle (Saale)

    Halle, Germany

  • Universitaetsklinikum Schleswig-Holstein Campus Kiel

    Kiel, Germany

  • Universitaetsmedizin Mannheim GmbH

    Mannheim, Germany

  • Johannes Wesling Klinikum Minden

    Minden, Germany

  • Universitaetsklinikum Muenster

    Münster, Germany

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.